secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0000885725-24-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY
--------------------------------------------------------------------------------

- Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.
- GAAP EPS $0.32 (down from $0.34), adjusted EPS $0.63 (vs guidance $0.57-0.59).
- Cardiovascular segment grew 25.0% reported; MedSurg grew 10.3%.
- Full-year 2024 organic sales guidance ~15%; Q4 organic guidance 14-16%.
- Completed acquisition of Silk Road Medical for stroke prevention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/0000885725-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/bsx-20241023.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer